Первая клетка. И чего стоит борьба с раком до последнего

Liu M. C. et al. Plasma Cell-Free DNA (cfDNA) Assays for Early Multi-Cancer Detection: The Circulating Cell-Free Genome Atlas (CCGA) Study. Annals of Oncology. 29, supplement 8 (2018): mdy269.048.

Sallam R. M. Proteomics in Cancer Biomarkers Discovery: Challenges and Applications. Disease Markers, 2015. doi:10.1155/2015/321370.

Taylor D., Gercel-Taylor C. MicroRNA Signatures. www.gynecologiconcology-online.net/article/S0090–8258(08)00343–0/fulltext

Peng L. Tissue and Plasma Proteomics for Early Stage Cancer Detection. Molecular Omics. 14 (2018): 405–423.

Tajmul M. D. et al. Identification and Validation of Salivary Proteomic Signatures for Non-Invasive Detection of Ovarian Cancer. International Journal of Biological Macromolecules. 108 (2018): 503–514.

Simpson R. J. et al. Proteomic Profiling of Exosomes: Current Perspectives. Proteomics. 8 (2008): 4083–4099.

Chen Z. et al. Current Applications of Antibody Microarrays. Clinical Proteomics. 15, no. 7 (2018). doi:10.1186/s12014-018-9184-2.

Halvaei S. Exosomes in Cancer Liquid Biopsy: A Focus on Breast Cancer. Nucleic Acid. 10 (2018): 131–141.

Xu R. et al. Extracellular Vesicles in Cancer – Implications for Future Improvements in Cancer Care. Nature Reviews Clinical Oncology. 15, no. 10 (2018): 617–638.

Valentino A. et al. Exosomal MicroRNAs in Liquid Biopsies: Future Biomarkers for Prostate Cancer. Clinical and Translational Oncology. 19 (2017): 651–657.

Rajagopal C., Harikumar K. B. The Origin and Functions of Exosomes in Cancer. Frontiers in Oncology, March 20, 2018. doi:10.3389/fonc.2018.00066.

Rani S. et al. Isolation of Exosomes for Subsequent mRNA, MicroRNA, and Protein Profiling. Methods in Molecular Biology. 784 (2011): 181–195.

Liu F. et al. Exosome-Total-Isolation-Chip (ExoTIC) Device for Isolation of Exosome-Based Biomarkers. US patent application 16/073,577, filed 2019.

Alix-Panabieres C., Pantel K. Circulating Tumor Cells: Liquid Biopsy of Cancer. Clinical Chemistry. 59 (2013): 110–118.

Green B. J. et al. Beyond the Capture of Circulating Tumor Cells: Next-Generation Devices and Materials. Angewandte Chemie International Edition. 55 (2016): 1252–1265.

Vona G. et al. Isolation by Size of Epithelial Tumor Cells: A New Method for the Immunomorphological and Molecular Characterization of Circulating Tumor Cells. American Journal of Pathology. 156, no. 1 (2000): 57–63.

Paterlini-Brechot P., Benali N. L. Circulating Tumor Cells (CTC) Detection: Clinical Impact and Future Directions. Cancer Letters. 253, no. 2 (2007): 180–204.

Hood L., Friend S. H. Predictive, Personalized, Preventive, Participatory (P4) Cancer Medicine. Nature Reviews Clinical Oncology. 8 (2011): 184–187.

Cohen J. D. et al. Combined Circulating Tumor DNA and Protein Biomarker-Based Liquid Biopsy for the Earlier Detection of Pancreatic Cancers. PNAS. 114, no. 38 (2017): 10202–10207.

Wang Qing et al. Mutant Proteins as Cancer-Specific Biomarkers. PNAS. 108, no. 6 (2011): 2444–2449.

Lennon A. M. et al. The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia? Cancer Research. 74, no. 13 (2014): 3381–3389.

Moses H., III et al. Financial Anatomy of Biomedical Research. JAMA. 294, no. 11 (2005): 1333–1342.